<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>List of antiretroviral drugs currently in the market</td>
<td>7</td>
</tr>
<tr>
<td>4.1</td>
<td>Solubility of Lamivudine in various pH media</td>
<td>56</td>
</tr>
<tr>
<td>4.2</td>
<td>In-vitro dissolution rate of Lamivudine tablets 150 mg, in various pH media</td>
<td>57</td>
</tr>
<tr>
<td>4.3</td>
<td>UV $\lambda_{\text{max}}$ values of Lamivudine in different pH media</td>
<td>59</td>
</tr>
<tr>
<td>4.4</td>
<td>Standard calibration values of Lamivudine in different pH media.</td>
<td>61</td>
</tr>
<tr>
<td>4.5</td>
<td>Formulation and physical characteristics of designed controlled release matrix tablets of Lamivudine</td>
<td>64</td>
</tr>
<tr>
<td>4.6</td>
<td>In vitro dissolution of designed controlled release matrix tablets of Lamivudine</td>
<td>65</td>
</tr>
<tr>
<td>4.7</td>
<td>Release kinetics of Lamivudine matrix tablets</td>
<td>65</td>
</tr>
<tr>
<td>4.8</td>
<td>Optimized formulation of Lamivudine matrix tablets</td>
<td>67</td>
</tr>
<tr>
<td>4.9</td>
<td>Dissolution of optimized Lamivudine matrix tablets</td>
<td>68</td>
</tr>
<tr>
<td>4.10</td>
<td>Tablet dimensions for 11 mm flat faced round HPMCK100M matrix tablets with increasing surface area/volume values</td>
<td>74</td>
</tr>
<tr>
<td>4.11</td>
<td>Tablet dimensions for flat faced round HPMCK100M matrix tablets with constant surface area values</td>
<td>75</td>
</tr>
<tr>
<td>4.12</td>
<td>Tablet dimensions for flat faced round HPMC</td>
<td>77</td>
</tr>
</tbody>
</table>
K100M matrix tablets with constant surface area/volume values

4.13 Percent of moisture uptake of Lamivudine granules and tablets from formulation F-7 (HPMC and PEO)

4.14 Dissolution profile, Hardness and assay of Lamivudine matrix tablets during stability

4.15 Particle size distribution, % drug content and Entrapment efficiency of Lamivudine microcapsules prepared with different polymers

4.16 In vitro dissolution data of Lamivudine microcapsules prepared with different polymers

4.17 Release kinetics of Lamivudine microcapsules prepared with different polymers

4.18 Estimation of % drug content of accelerated stability study samples of Lamivudine microcapsules at 40°C/75% RH

5.1 Solubility of Zidovudine in various pH media

5.2 In-vitro dissolution studies of zidovudine tablets 300 mg, in various pH media

5.3 UV $\lambda_{\text{max}}$ values of zidovudine in different pH media

5.4 Standard calibration values of zidovudine in different pH media.

5.5 Formulation and physical characteristics of designed controlled release matrix tablets of Zidovudine with HPMCK100M
5.6 In vitro dissolution of controlled release matrix tablets of Zidovudine with HPMC K100 M

5.7 In vitro release kinetic data of Zidovudine matrix tablets with HPMC K 100M

5.8 Formulations designed controlled release matrix tablets of Zidovudine with PEO WSR 303

5.9 Physical characteristics of designed controlled release matrix tablets of Zidovudine with PEO WSR 303

5.10 Formulations of designed controlled release matrix tablets of Zidovudine Carbopol 971

5.11 Physical characteristics of designed controlled release matrix tablets of Zidovudine with Carbopol 971

5.12 Formulations of designed controlled release matrix tablets of Zidovudine with Eudragit L 100

5.13 Physical characteristics of designed controlled release matrix tablets of Zidovudine with Eudragit L 100

5.14 Percent retained of granules during particle size distribution of Zidovudine with different polymers and granulation fluids

5.15 Cumulative percent retained of granules during particle size distribution of Zidovudine with different polymers and granulation fluids

5.16 In vitro dissolution of controlled release matrix tablets of Zidovudine – PEO with different granulation fluids

5.17 Release kinetics of controlled release matrix
tablets of Zidovudine-PEO with different granulation fluids

5.18 Cumulative percent of drug released from Zidovudine-carbopol matrix tables

5.19 Release kinetics of Zidovudine-Carbopol with IPA granulation

5.20 Percent drug release of Zidovudine-EudragitL100 matrix tablets with different granulation fluids

5.21 Release kinetics of Zidovudine-Eudragit L100 matrix tablets with different granulation fluids

5.22 Sieve analysis, drug content and entrapment efficiency of zidovudine microcapsules

5.23 Percent drug release of Zidovudine microcapsules with Eudragit RL 100 and Eudragit RS 100

5.24 Release kinetics of Zidovudine microcapsules with Eudragit RL 100 and Eudragit RS 100

6.1 Solubility data of Stavudine in various pH media

6.2 In-vitro dissolution profiles of Stavudine capsules 30 mg, in various pH media

6.3 UV $\lambda_{max}$ values of Stavudine in different pH media

6.4 Standard calibration values of Stavudine in different pH media

6.5 Formulation of designed immediate release granules of Stavudine (FS-1)

6.6 Formulation of designed Extended release granules of Stavudine (FS-2, FS-3 and FS-4)
6.7 Release kinetics of Stavudine extended release matrix tablets

6.8 In vitro dissolution studies of extended release stavudine matrix tablets (FS-2, FS-3 and FS-4)

6.9 Formulation and physical characteristics of the prepared compression coated matrix tablets of stavudine

6.10 In-vitro dissolution of prepared compression coated matrix tablets

6.11 Formulation of immediate release granules in bi-layered matrix tablets

6.12 Physical characteristics of the prepared bi-layer matrix tablets

6.13 In-vitro dissolution profiles of prepared bi-layered matrix tablets

6.14 In-vitro dissolution of extended release layer of the prepared bi layer matrix tablets

6.15 Formulation of immediate release granules for capsule filled mini tablets of 5 mm

6.16 Physical and chemical properties of the prepared immediate and extended release capsule filled mini tablets

6.17 Comparative dissolution of extended release matrix tablets of FS-9 with FS-2 matrix tablets

6.18 Physical and chemical properties of the prepared immediate and extended release multiple mini tablets

6.19 Comparative dissolution of extended release multiple mini matrix tablets off FS-11 with FS-9, FS-2 matrix tablets
6.20 Physical characteristics of stavudine microcapsules

6.21 In vitro dissolution profiles of stavudine microcapsules

6.22 Release kinetics of stavudine microcapsules

7.1 Standard calibration curve of Lamivudine in rabbit plasma

7.2 Plasma concentration profiles of Lamivudine immediate release tablets at different time intervals

7.3 Pharmacokinetic data of Lamivudine 100 mg immediate release tablets (R)

7.4 Plasma concentration profiles of Lamivudine immediate release tablets at different time intervals

7.5 Pharmacokinetic data of Lamivudine 100 mg extended release tablets (T)